Free Trial
NASDAQ:CGEM

Cullinan Therapeutics (CGEM) Stock Price, News & Analysis

Cullinan Therapeutics logo
$7.72 +0.37 (+5.03%)
As of 12:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Cullinan Therapeutics Stock (NASDAQ:CGEM)

Key Stats

Today's Range
$7.38
$7.79
50-Day Range
$7.13
$9.08
52-Week Range
$6.85
$21.01
Volume
117,327 shs
Average Volume
514,209 shs
Market Capitalization
$455.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Buy

Company Overview

Cullinan Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

CGEM MarketRank™: 

Cullinan Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 771st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cullinan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cullinan Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cullinan Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.04) to ($3.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cullinan Therapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cullinan Therapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cullinan Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cullinan Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.59% of the float of Cullinan Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cullinan Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cullinan Therapeutics has recently decreased by 3.56%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cullinan Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cullinan Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.59% of the float of Cullinan Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cullinan Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cullinan Therapeutics has recently decreased by 3.56%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Cullinan Therapeutics this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cullinan Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.07% of the stock of Cullinan Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cullinan Therapeutics' insider trading history.
Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CGEM Stock News Headlines

President Trump’s Project MAFA
President Trump’s Boldest Initiative Yet First came “Make America Great Again” (MAGA)… Then came “Make America Healthy Again” (MAHA)… Now comes President Trump’s boldest initiative yet. After a gathering in D.C. with some of the most powerful people in the world, Jeff Brown is now revealing the full details on “Project MAFA.” It’s a revolutionary plan to return America to an era of sound money, eliminate our looming debt disaster, kick off a Golden Century, and more – by July 25. Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. Jeff Brown is sharing the details Wednesday, July 16, at 8 p.m. ET – including the name of a stock set to profit.
See More Headlines

CGEM Stock Analysis - Frequently Asked Questions

Cullinan Therapeutics' stock was trading at $12.18 at the beginning of 2025. Since then, CGEM stock has decreased by 39.7% and is now trading at $7.35.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04.

Cullinan Therapeutics (CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
5/08/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGEM
CIK
1789972
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$36.00
Low Price Target
$22.00
Potential Upside/Downside
+308.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$167.38 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$10.14 per share
Price / Book
0.72

Miscellaneous

Free Float
55,433,000
Market Cap
$433.72 million
Optionable
Optionable
Beta
-0.08
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CGEM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners